# Cohance Lifesciences (NSE: COHANCE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/COHANCE · Pivot · prices to 22 Oct 2026

Cohance Lifesciences (NSE: COHANCE) closed at ₹460.30 on 22 Oct 2026, down 0.25% on the day. With a market capitalisation of ₹17,363 Cr, it ranks 378th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 98.6× trailing earnings, against a return on equity of 15.8% in FY25. Over the past year the share price has fallen 46.9%. Its 52-week range is ₹266.70 (9 Mar 2026) to ₹903.40 (23 Oct 2025); the last close is 49.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹422 Cr (−23.1% year on year) and net profit −₹45 Cr (−197.4%), on a consolidated basis. Promoters held 57.49% of the company as of 30 Jun 2026; 94.56% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹460.30 |
| Market cap | ₹17,363 Cr |
| P/E (trailing) | 98.6 |
| ROE | 15.8% (FY25) |
| ROCE | 13.4% (FY25) |
| Debt to equity | 0.05 |
| 52-week high | ₹903.40 (23 Oct 2025) |
| 52-week low | ₹266.70 (9 Mar 2026) |
| 1-year return | −46.9% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹422 Cr | −23.1% | −₹45 Cr | −197.4% | −₹0.63 |
| Q4 FY26 | ₹619 Cr | +54.0% | ₹8 Cr | −78.5% | ₹0.51 |
| Q3 FY26 | ₹545 Cr | +77.3% | ₹29 Cr | −65.2% | ₹0.96 |
| Q2 FY26 | ₹556 Cr | +115.6% | ₹66 Cr | −19.0% | ₹1.94 |
| Q1 FY26 | ₹549 Cr | +138.1% | ₹46 Cr | −23.6% | ₹1.28 |
| Q4 FY25 | ₹402 Cr | +58.9% | ₹39 Cr | −27.4% | ₹1.65 |
| Q3 FY25 | ₹307 Cr | +39.7% | ₹83 Cr | +78.2% | ₹3.26 |
| Q2 FY25 | ₹258 Cr | +11.5% | ₹82 Cr | +3.0% | ₹3.23 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,198 Cr | ₹265 Cr |
| FY24 | ₹1,051 Cr | ₹300 Cr |
| FY23 | ₹1,340 Cr | ₹411 Cr |
| FY22 | ₹1,320 Cr | ₹413 Cr |
| FY21 | ₹1,010 Cr | ₹309 Cr |
| FY20 | ₹834 Cr | ₹269 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 57.49%
- Foreign institutions: 6.50%
- Domestic institutions: 20.09%
- Non-institutions: 15.92%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Granules India](https://app.pivotnow.in/stock/GRANULES) | ₹807.65 | ₹20,245 Cr | 33 | 11.7% |
| [Indraprastha](https://app.pivotnow.in/stock/IGL) | ₹141.87 | ₹19,601 Cr | 12.8 | 27.0% |
| [Caplin Point Laboratories](https://app.pivotnow.in/stock/CAPLIPOINT) | ₹2,227.80 | ₹17,096 Cr | 25 | 19.3% |
| [Pfizer](https://app.pivotnow.in/stock/PFIZER) | ₹3,712.10 | ₹16,876 Cr | 23.5 | 17.2% |
| [Shilpa Medicare](https://app.pivotnow.in/stock/SHILPAMED) | ₹880.90 | ₹16,836 Cr | 70.9 | 9.4% |
| [Onesource Specialty Pharma](https://app.pivotnow.in/stock/ONESOURCE) | ₹1,378.00 | ₹15,796 Cr | — | −1.3% |

## Questions and answers

### What is the share price of Cohance Lifesciences today?

Cohance Lifesciences (NSE: COHANCE) last closed at ₹460.30 on 22 Oct 2026. Its 52-week high is ₹903.40 and its 52-week low is ₹266.70.

### What is the market cap of Cohance Lifesciences?

Cohance Lifesciences' market capitalisation is ₹17,363 Cr (₹17,363 Cr) at the 22 Oct 2026 close, ranking 378th among the NSE companies Pivot tracks.

### What is the P/E ratio of Cohance Lifesciences?

Cohance Lifesciences trades at a trailing P/E of 98.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 25.

### What is the ROE and ROCE of Cohance Lifesciences?

Return on equity was 15.8% in FY25 and return on capital employed was 13.4% in FY25 (consolidated figures).

### Is Cohance Lifesciences a debt-free company?

Cohance Lifesciences is close to debt-free: its debt-to-equity ratio was 0.05 in FY25.

### What were Cohance Lifesciences' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Cohance Lifesciences reported revenue of ₹422 Cr, −23.1% year on year, and net profit of −₹45 Cr, −197.4% year on year.

### How has Cohance Lifesciences stock performed over the last year?

Cohance Lifesciences' share price has fallen 46.9% over the past year, +5.0% over three months and +0.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Cohance Lifesciences?

As of 30 Jun 2026: promoters 57.49%, foreign institutions 6.50%, domestic institutions 20.09%, non-institutions 15.92%. 94.56% of promoter shares were pledged.

### Who are Cohance Lifesciences' competitors?

The listed Pharma & Healthcare companies closest to Cohance Lifesciences by market cap are Granules India, Indraprastha, Caplin Point Laboratories, Pfizer, Shilpa Medicare and Onesource Specialty Pharma.

### Is Cohance Lifesciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Cohance Lifesciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on COHANCE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.